-24.30 (-1.91%) Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC have received approval for TOSYMRA (previously known as DFN-02) from the US Food and Drug Administration (USFDA). TOSYMRA is indicated for the acute treatment of migraine with or without aura in adults.
TOSYMRA is the latest product to join the Promius Pharma acute migraine treatment portfolio. The company is working toward commercialization of this product.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.